Manal Haddad

pharmaceuticals

Slow revenue growth in the pharmaceutical industry for the coming 5 years

Good things can’t last forever. Commerce is constantly changing, with ebbs and flows in revenue a natural part of conducting business activity. Unfortunately for the pharmaceutical industry, one of these low periods has emerged again. Due to an assortment of factors, slow revenue growth appears to be the norm throughout the industry for the next

Slow revenue growth in the pharmaceutical industry for the coming 5 years Read More »

It is becoming more difficult for brands to survive in the Pharmaceuticals industry

Success in today’s global market depends on versatility and consumer-oriented services. If the consumer interest is not present, market failure will ensure, the impression of quality of one’s product or service. This is the issue facing today’s pharmaceuticals industry, where it is becoming more difficult for brands to survive financially. Many organizations within the sector

It is becoming more difficult for brands to survive in the Pharmaceuticals industry Read More »

Increased shrinkage and fraud affecting stock control in the pharmaceuticals industry

Among the many management functions performed in the pharmaceutical trade, few have more of a direct impact than inventory control. Purchasing policies gain a greater amount of attention and it certainly deserves heightened emphasis. However, sound purchasing policies and inventory control are closely intertwined; the one function cannot be effective without the strength of the

Increased shrinkage and fraud affecting stock control in the pharmaceuticals industry Read More »

Rising costs vs. maintaining competitive pricing in the Pharmaceuticals industry

The pharmaceutical industry is in some regards not unique from other industries. Pharmaceutical companies design and manufacture commodities that must be sold for a profit in order for the company to survive and grow. Competitive pricing is a key component toward accomplishing this. However, the rising costs incurred by drug companies due to regulation and

Rising costs vs. maintaining competitive pricing in the Pharmaceuticals industry Read More »

Scroll to Top